Quelle: - pixabay.com:
Google
PR Newswire  | 

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN, AVDL, EVOK, and TRUE

PR Newswire

play Anhören
share Teilen
feedback Feedback
copy Kopieren
newsletter
font_big Schrift vergrößern
Avadel Pharmaceuticals plc 21,35 $ Avadel Pharmaceuticals plc Chart -0,02%
Zugehörige Wertpapiere:
Evoke Pharma Inc 10,92 $ Evoke Pharma Inc Chart -0,18%
Zugehörige Wertpapiere:
Huntington Bancshares Inc 16,98 $ Huntington Bancshares Inc Chart -0,70%
Zugehörige Wertpapiere:
Truecar 2,195 $ Truecar Chart +1,15%
Zugehörige Wertpapiere:

NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

  • Huntington Bancshares Incorporated (NASDAQ: HBAN) related to its merger with Cadence Bank. Under the terms of the proposed transaction, Cadence shareholders will receive 2.47 shares of Huntington common stock for each share of Cadence common stock.

Click here for more information https://monteverdelaw.com/case/huntington-bancshares-incorporated/ .  It is free and there is no cost or obligation to you.

  • Avadel Pharmaceuticals plc (NASDAQ: AVDL) related to its sale to Alkermes plc. Under the terms of the proposed transaction, Avadel shareholders will receive $18.50 per share, plus a non-transferable contingent value right entitling holders to a potential additional cash payment of $1.50 per share, contingent upon final FDA approval of LUMRYZ™ for the treatment of idiopathic hypersomnia in adults by the end of 2028.

Click here for more information https://monteverdelaw.com/case/avadel-pharmaceuticals-plc/ .  It is free and there is no cost or obligation to you.

  • Evoke Pharma, Inc. (NASDAQ: EVOK) related to its sale to QOL Medical, LLC. Under the terms of the proposed transaction, Evoke shareholders will receive $11.00 per share in cash.

Click here for more information https://monteverdelaw.com/case/evoke-pharma-inc/ .  It is free and there is no cost or obligation to you.

  • TrueCar, Inc. (NASDAQ: TRUE) related to its sale to Fair Holdings, Inc. Upon completion of the proposed transaction, TrueCar shareholders will receive $2.55 in cash per share.

Click here for more info https://monteverdelaw.com/case/truecar-inc-2/ . It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

  1. Do you file class actions and go to Court?
  2. When was the last time you recovered money for shareholders?
  3. What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.


Für dich aus unserer Redaktion zusammengestellt

Dein Kommentar zum Artikel im Forum

Jetzt anmelden und diskutieren Registrieren Login

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Weitere Artikel des Autors

Themen im Trend